Rolapitant Well-tolerated for Chemotherapy-Induced Nausea, Vomiting

Share this content:
Rolapitant is well tolerated and showed superiority over active control for the prevention of chemotherapy-induced vomiting and nausea.
Rolapitant is well tolerated and showed superiority over active control for the prevention of chemotherapy-induced vomiting and nausea.

Rolapitant in combination with a 5-HT3 receptor and dexamethasone is well tolerated and showed superiority over active control for the prevention of chemotherapy-induced vomiting and nausea after the administration of moderately emetogenic chemotherapy or an anthracycline and cyclophosphamide, according to a study published online ahead of print in the The Lancet Oncology.

Investigators conducted a global, randomized, double-blind active-controlled, phase 3 study at 170 cancer centers in 23 countries.

Patients qualified if they had not received moderately or highly emetogenic chemotherapy, with a Karnofsky performance score of 60 or higher, and a predicted life expectancy of 4 months or longer.

Between March 5, 2012, and September 6, 2013, 1,369 patients were randomized to receive either 180 mg rolapitant (n=684) or placebo (n=685) 1 to 2 hours before administration of the moderately emetogenic agent.

All patients received 2 mg granisetron and 20 mg dexamethasone on day 1 (except for those receiving taxanes as part of moderately emetogenic chemotherapy, who received dexamethasone according to the package insert) and granisetron (2 mg orally) on days 2 to 3.

A greater proportion of patients receiving rolapitant had complete responses in the delayed phase than did those receiving active control 71% versus 62%, respectively; P=0.0002.

RELATED: Ipilimumab Can Be Infused Safely Over 30 Minutes

With regard to safety, the incidence of adverse events was similar between the rolapitant and control groups, with the most frequently reported treatment-related treatment-emergent adverse events being fatigue, constipation, and headache.

For the first cycle, the most common grade3-4 adverse events in the rolapitant versus placebo was neutropenia 5% versus 3%. No serious adverse event was treatment-related, and no treatment-related treatment-emergent adverse event resulted in death.

Reference

  1. Shwartzberg LS, Modiano MR, Rapoport B, et al. Safety and Efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in paitents with cancer: a randomised, active-controlled, double-blind phase 3 trial. The Lancet Oncol. 2015. [epub ahead of print]. doi: 10.1016/S1470-2045(15)00034-0.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs